Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021
Deprescribing in Epilepsy
JAMA Neurol 77:673-674, Terman, S.W.,et al, 2020
Efficacy and Tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Neurol 91:82-90, Kanner, A.M.,et al, 2018
Efficacy and Tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy
Neurol 91:74-81, Kanner, A.M.,et al, 2018
Migraine
NEJM 377:553-561, Charles, A., 2017
Triptans for Symptomatic Treatment of Migraine Headache
BMJ 348:g2285, Pringsheim, T. & Becker, W.J., 2014
Myasthenia in Pregnancy: Best Practice Guidelines from a UK Multispecialty Working Group
JNNP 85:538-543, Norwood, F.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Using Dabigatran in Patients with Stroke A Practical Guide for Clinicians
Stroke 43:271-279, Alberts, M.J.,et al, 2012
Statins and Intracerebral Hemorrhage
Arch Neurol 69:39-45,13, Hackam,D.G,et al, 2012
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Evidence-Based Guideline: Pharmacologic Treatment of Chorea in Huntington Disease
Neurol 79:597-603, Armstrong, M.J. & Miyasaki, J.M., 2012
Hyperosmolar Therapy for Raised Intracranial Pressure
NEJM 367:746-752, Ropper, A.H., 2012
Intravenous Thrombolytic Therapy for Acute Ischemic Stroke
NEJM 364:22, Wechsler, L.R., 2011
Evidence-based guideline update: Treatment of Essential Tremor
Neurol 77:1752-1755, Zesiewicz, T.A.,et al, 2011
Assessment: Symptomatic Treatment for Muscle Cramps (an Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:691-696, Katzberg,H.D.,et al, 2010
Evidence Report: The Efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:1463-1470, Marriott,J.J., et al, 2010
Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
Triptan Therapy in Migraine
NEJM 363:63-70, Loder,E., 2010
Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010
Pregnancy and Fetal Outcomes After Interferon-b Exposure in Multiple Sclerosis
Neurol 75:1794-1802, Amato,M.P.,et al, 2010
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W)
Stroke 39:1482-1486,1406, Healey,J.S.,et al, 2008
Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis
Radiology 242:647-649, Kuo,P.H.,et al, 2007
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007
Position Statement on the Coverage of Anticonvulsant Drugs for the Treatment of Epilepsy
Neurol 68:1249-1250,1245, Liow,K.,et al, 2007
Natalizumab for Multiple Sclerosis
NEJM 356:2622-2629, Ransohoff,R.M., 2007
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Intracerebral Hemorrhage Associated with Oral Anticoagulant Therapy
Stroke 37:256-262, Steiner, T.,et al, 2006
Chronic Daily Headache
NEJM 354:158-165, Dodick,D.W., 2006
Adult Epilepsy
Lancet 367:1087-1100, Duncan,J.S.,et al, 2006
Practice Parameter: Corticosteroid Treatment of Duchenne Dystrophy
Neurol 64:13-20, Moxley,R.T. III.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Use of Antihypertensive Agents in the Management of Patients with Acute Ischemic Stroke
Neurol 63:318-323, Lindenauer,P.K.,et al, 2004
The Use of Mitoxantrone (Novantrone) for the Treatment of Multiple Sclerosis
Neurol 61:1332-1338, Goodin,D.S.,et al, 2003
Practice Patterns of Neurologists Regarding Bone and Mineral Effefcts of Antiepileptic Drug Therapy
Arch Neurol 58:1369-1374,1352, Valmadrid,C.,et al, 2001
Intravenous Tissue-Type Plasminogen Activator Therapy for Ischemic Stroke
Arch Neurol 58:2009-2013, Grotta,J.C.,et al, 2001
Practice Parameter: Evidence-Based Guidelines for Migraine Headache (an Evidence-Based Review)
Neurol 55:754-763, Silberstein,S.D. et al, 2000
Practice Advisory:The Use of Felbamate in the Treatment of Patients with Intractable Epilepsy, Report of the quality Standards Subcommittee of the AAN and the American Epilepsy Society
Neurol 52:1540-1545, French,J.,et al, 1999
Initial Clinical Experience with IV Tissue Plasminogen Activator for Acute Ischemic Stroke:A Multicenter Survey
Neurol 53:424-427, Tanne,D.,et al, 1999
Systematic Review of Evidence on Thrombolytic Therapy for Acute Ischaemic Stroke
Lancet 350:607-614, Wardlaw,J.M.,et al, 1997
Anticytokine Antibodies in Beta Interferon-Trated MS Patients and the Need for Testing
Neurol 49:647-650, Pachner,A.R., 1997
Thrombolytic Therapy for Acute Ischemic Stroke-Summary Statement
Report of the Quality Standards Subcommittee of the AAN, Neurol 47:835-8391996., , 1996
Guidelines for Physicians with Patients on IFNB-1b:The Use of an Assay for Neutralizing Antibodies (NAB)
Neurol 47:865-866, Paty,D.,et al, 1996
Epilepsy
JNNP 57:264-277, Chadwick,D., 1994